Clinical science
Stem Cell Therapy and Exosomes in Orthopedic Medicine
Evidence calibration, regulatory standards and informed consent: terminology, product characterization, the condition-by-condition evidence for joints, tendon, bone and spine, the exosome translational gap, Section 361 and 351, IND boundaries, MedWatch reporting and chain of custody
Faculty: Sonya Pearson, Ph.D., J.D. and Mandy Hayes, FNP-C
- 4 hours
- 8
- 80%
- CEU and CME pending approval

Enrollment opens soon
- 4 hours
- 8
- 80%
CEU and CME credit pending approval
Modules can be bought one at a time or as the full course.
What you will be able to do
- Distinguish embryonic and adult stem cells, culture-expanded mesenchymal stromal cells, bone marrow aspirate concentrate and cell-free extracellular vesicles, and explain why cell-based and exosome products are separate biological and regulatory entities
- Evaluate a cell or exosome product's source, isolation method, identity, purity, potency and stability documentation, and identify what a product dossier is missing
- Grade the human evidence for cell-based injections in knee, hip and glenohumeral osteoarthritis, focal cartilage lesions and tendinopathy, separating trial results from mechanistic plausibility
- Summarize the evidence for cellular adjuncts in femoral head osteonecrosis, fracture nonunion and intradiscal treatment of degenerative disc disease
- Explain the gap between in vitro and animal exosome data and human clinical outcomes, including the effect of isolation and purification variability
- Apply the Section 361 and Section 351 framework and the IND rules to an orthobiologic, and state when MedWatch and IND safety reporting apply
- Conduct an informed consent discussion that states regulatory status, evidence certainty, alternatives and costs accurately, and document product chain of custody
- Recognize deceptive orthobiologic marketing claims, including the claim that an active IND proves safety or efficacy, and replace them with accurate statements
Modules
Essential Terminology
- Stem Cells, MSCs, BMAC and Exosomes: Four Different Things
Biology and Product Characterization
- Cell Sources and Isolation Methods
- Identity, Purity, Potency, Stability and the Missing Cargo Standard
Condition-Specific Musculoskeletal Evidence
- Knee Osteoarthritis: What the Trials Show
- Hip and Glenohumeral Osteoarthritis and Focal Cartilage Lesions
- Tendinopathy
Bone Healing, Osteonecrosis and Spine
- Femoral Head Osteonecrosis and Fracture Nonunion
- Intradiscal Cell Therapy for Degenerative Disc Disease
Exosomes and the Translational Evidence Gap
- From the Dish to the Joint: Where Exosome Evidence Stops
- Isolation and Purification Variability
FDA Regulatory Status, Consent and Ethical Compliance
- Section 361, Section 351 and the IND Boundary
- Informed Consent, Chain of Custody and MedWatch
Case-Based Clinical Applications
- Case 1: An Uncharacterized Product for Knee Osteoarthritis
- Case 2: Early-Stage Femoral Head Osteonecrosis
- Case 3: Achilles Tendinopathy and a Marketing Claim
Knowledge Assessment and Review
- Review: Evidence Calibration on One Page
Faculty
Sonya Pearson, Ph.D., J.D.
Lead Author and Curriculum Development Director
Mandy Hayes, FNP-C
Clinical Reviewer
Written for
- Orthopedic surgeons
- Sports medicine physicians
- Physical medicine and rehabilitation physicians
- Nurse practitioners and physician assistants in orthopedic and sports medicine practice
To complete the course
- Acknowledge the scope of practice and FDA status notices
- Open every lesson in all eight modules and all three cases
- Score 80% or higher on the post-test
- Complete the course evaluation
Continuing education credit for this course is pending approval by an accredited provider. Until it is approved, no CE credit is awarded. Certificates are issued only for the full course; a single module does not earn one.
